• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Alcon introduces new medical device for dry eye treatment

Article

As an all-in-one handheld device, eyecare practitioners can tailor patients’ needs for MGD treatment in both eyes in approximately 8 to 12 minutes.

Imaging technology enables eyecare practitioners to tailor MGD treatment patients’ needs for treatment in both eyes in approximately 8 to 12 minutes

The Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System can treat patients' needs in 8 to 12 minutes for both eyes. Image credit: Alcon.


Alcon announced Tuesday the launch of its Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System for the treatment of dry eye.

As an all-in-one handheld device, the company’s latest innovation is designed to deliver gentle warming and pressure directly to patients’ eyelids in order to unblock meibomian glands.

Imaging technology enables eyecare practitioners to tailor MGD treatment to patients’ needs in approximately 8 to 12 minutes for both eyes, according to a company news release.

Additionally, patients are able to view both their meibomian glands and treatment through infared imaging and HD video of the procedure. They may also experience results in as little as one week, the company reported.

Related Videos
Megan Cavet, PhD
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Andrew Pucker, OD, PhD
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
Marc R Bloomenstein, OD, FAAO, chats with Optometry Times about the benefits of Vevye in the treatment of dry eye
R Tracy Williams, OD, FAAO, details his experience as a sports team optometrist
© 2024 MJH Life Sciences

All rights reserved.